Innovation Pharmaceuticals Inc.: Innovation Pharmaceuticals Analyzing Full Dataset for Its Brilacidin COVID-19 Clinical Trial; Company Evaluating New Pipeline Opportunities for 2022

WAKEFIELD, MA / ACCESSWIRE / December 7, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provides shareholders with perspectives on the

Related Keywords

United States ,Leo Ehrlich ,Exchange Commission ,Innovation Pharmaceuticals Inc ,Contract Development ,Innovation Pharmaceuticals ,Inflammatory Bowel Disease ,Ulcerative Colitis ,Oral Mucositis ,Manufacturing Organizations ,Chief Executive Officer ,Looking Statements ,Private Securities Litigation Reform Act ,Innovation ,Pharmaceuticals ,Analyzing ,Bull ,Dataset ,Brilacidin ,Covid ,Linical ,Trial ,Company ,Valuating ,Pipeline ,Opportunities ,022 ,